Business, energy, technology, markets and global industry news from Business News Today

Merck & Co.

PharmaDeviceNews Merck & Co.
Representative image of biopharma laboratory research. Gilead Sciences and Merck’s latest Phase 3 updates highlight the promise of once-weekly HIV treatment with islatravir and lenacapavir, while raising fresh questions over Trodelvy’s lung cancer expansion strategy.
Pharma & Biotech

Gilead and Merck pipeline update reveals promise in HIV and pressure in oncology

Gilead and Merck gain HIV momentum but face fresh oncology questions. See why this split pipeline update matters.

Read More
Representative image of a lung cancer treatment setting, as OptiTROP-Lung05 data put sacituzumab tirumotecan at the centre of the first-line NSCLC immunotherapy debate.
Pharma & Biotech

Can TROP2 ADCs reshape first-line NSCLC after Kelun-Biotech’s OptiTROP-Lung05 win?

A TROP2 ADC just pushed past pembrolizumab alone in first-line lung cancer. See why OptiTROP-Lung05 matters now.

Read More
Representative image: Advanced lung cancer research and oncology treatment planning are becoming central to the debate over whether Kelun-Biotech’s sacituzumab tirumotecan and pembrolizumab combination can reshape first-line NSCLC care.
Pharma & Biotech

Why Kelun-Biotech’s sac-TMT review could reshape China’s lung cancer ADC market

ADC ambition meets Keytruda dominance. Kelun-Biotech’s sac-TMT filing could test how far TROP2 combinations can move in lung cancer.

Read More
Pharma & Biotech

Merck may have solved the hidden problem behind the oral PCSK9 race

Oral PCSK9 drugs need more than strong LDL data. Merck’s enlicitide paper tests whether peptide manufacturing can scale.

Read More
Representative image of biotech research technology for chronic myeloid leukemia drug development, highlighting how Merck & Co.’s Terns Pharmaceuticals acquisition could sharpen the race for next-generation targeted oncology therapies.
Features & Analysis

Why Merck’s Terns acquisition puts chronic myeloid leukemia back in the oncology dealmaking spotlight

Merck needs more than Keytruda. TERN-701 could make chronic myeloid leukemia a sharper test of its next oncology strategy.

Read More
Pharma & Biotech

Merck’s Terns deal clears antitrust hurdle as TERN-701 becomes bigger oncology test

Merck cleared one deal hurdle. TERN-701 still has to prove whether chronic myeloid leukemia can justify a $6.7 billion bet.

Read More
Merck’s IDVYNSO approval adds a new HIV option, but the real battle starts after viral suppression
Pharma & Biotech

FDA approval of IDVYNSO gives Merck a fresh HIV story, but will clinicians switch stable patients?

Merck’s IDVYNSO has won FDA approval in HIV. Read what the new two-drug regimen changes, where it fits, and what risks still matter.

Read More
Pharma & Biotech

How Merck’s ENFLONSIA could challenge existing infant RSV prevention pathways in Europe

European Union approval gives Merck’s ENFLONSIA a new opening in infant RSV prevention. Read what it means for rollout, reimbursement, and competition.

Read More
Pharma & Biotech

Why the Terns acquisition matters more for Merck’s long-term pipeline strategy than its near-term revenue

Merck has begun its tender offer for Terns Pharmaceuticals. Read what the deal could change for metabolic drug competition and pipeline strategy.

Read More
Pharma & Biotech

Can Merck’s enlicitide decanoate become the oral PCSK9 breakthrough cholesterol care has been waiting for?

Merck’s enlicitide decanoate beat oral rivals in Phase 3. Read what this could change for cholesterol care, PCSK9 adoption, and market strategy.

Read More